We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Screening System Designed To Detect Drugs That Block Drivers of Cancer Cell Growth

Screening System Designed To Detect Drugs That Block Drivers of Cancer Cell Growth content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

A new screening system developed by scientists at the UCLA Jonsson Comprehensive Cancer Center leverages redundancy in an important component of a cell – nucleotide metabolism – to help identify new drugs that specifically and potently block processes that are essential for cancer cell growth.

BACKGROUND

There are many small molecule kinase inhibitors, such as Gleevec, that have been developed to target cancers and other diseases. However, scientists still don’t fully understand the full effects of these drugs. Current screening methods do not capture the effects these inhibitors may have on other components of cells, such as biochemical metabolic networks. Using their understanding of metabolism, the team designed a new high-throughput screening system that allows for identification of selective inhibitors of metabolic pathways.

METHOD

Working with the Molecular Screening Shared Resource at UCLA, the team performed a large scale analyses of 430 kinase inhibitors that have annotated targets within cellular signaling pathways and many of which are currently being used in the clinic. Unexpectedly, multiple inhibitors were found to block nucleotide metabolism and their targets were revealed using mechanistic studies.

IMPACT

This new metabolism-focused screening approach can be a powerful tool in getting new insight into how existing drugs impact metabolic networks and could potentially provide a new understanding into how these drugs are working in the clinic. In addition to characterization of existing compounds that are already being used for treating cancers and other diseases, this screening method could one day also be applied to identify new small molecule modulators of currently un-targeted metabolic pathways – not only nucleotide metabolism – which can help lead to new drug discoveries.

Reference: Abt, et al. (2019) Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology DOI: https://doi.org/10.1016/j.chembiol.2019.10.012 

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.